-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Maintains Buy on Agilon Health, Lowers Price Target to $95

Benzinga·05/21/2026 14:09:58
Listen to the news
Benchmark analyst Bill Sutherland maintains Agilon Health (NYSE:AGL) with a Buy and lowers the price target from $13 to $95.